Aceto Corporation Subsidiary, Rising Pharmaceuticals, Inc, Launches Generic Version of Nasalide®

Published: Jun 04, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PORT WASHINGTON, N.Y., June 4, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, launched the 0.025% strength of Flunisolide Nasal Solution USP, an FDA approved generic version of Nasalide®. According to IMS Health data, U.S. market sales for Flunisolide, an anti-inflammatory steroid used to treat seasonal and perennial allergies, were approximately $37.3 million for the twelve months ended December 31, 2012. This is the eighth generic product launched by Rising Pharmaceuticals in fiscal 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news